259 related articles for article (PubMed ID: 19111388)
1. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
[TBL] [Abstract][Full Text] [Related]
2. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
3. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
[TBL] [Abstract][Full Text] [Related]
4. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
5. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
9. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
11. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
[TBL] [Abstract][Full Text] [Related]
12. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
15. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
17. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
18. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
19. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.
Hansel DE; Ashfaq R; Rahman A; Wanzer D; Yeo CJ; Wilentz RE; Maitra A
Am J Clin Pathol; 2005 Jan; 123(1):28-35. PubMed ID: 15762277
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
